Search results
Results from the WOW.Com Content Network
Osteopontin (OPN), also known as bone /sialoprotein I (BSP-1 or BNSP), early T-lymphocyte activation (ETA-1), secreted phosphoprotein 1 (SPP1), 2ar and Rickettsia resistance (Ric), [5] is a protein that in humans is encoded by the SPP1 gene (secreted phosphoprotein 1).
osteopontin (OPN) bone sialoprotein (BSP) dentin matrix protein 1 (DMP1) dentin sialophosphoprotein (DSPP) matrix extracellular phosphoglycoprotein (MEPE) The genes coding for members of the SIBLING protein family are similarly organized and are all located on human chromosome 4q21-23. [3]
OPN may stand for: . Osteopontin, a glycoprotein secreted by osteoblasts; Object Process Network, a simulation model meta-language; Optics & Photonics News, a magazine; Oneohtrix Point Never, recording alias of musician Daniel Lopatin
15891 Ensembl ENSG00000029559 ENSMUSG00000029306 UniProt P21815 Q61711 RefSeq (mRNA) NM_004967 NM_008318 RefSeq (protein) NP_004958 NP_032344 Location (UCSC) Chr 4: 87.8 – 87.81 Mb Chr 5: 104.45 – 104.46 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Bone sialoprotein (BSP) is a component of mineralized tissues such as bone, dentin, cementum and calcified cartilage. BSP is a ...
They synthesize dense, crosslinked collagen and specialized proteins in much smaller quantities, including osteocalcin and osteopontin, which compose the organic matrix of bone. In organized groups of disconnected cells, osteoblasts produce hydroxyapatite , the bone mineral , that is deposited in a highly regulated manner, into the inorganic ...
The interface is filled with non-collagenous proteins, mainly osteopontin (OPN) and osteocalcin (OC). [1] The osteopontin and osteocalcin form a sandwich structure with HAP minerals at nano-scale. The nano Interfaces are less than 2 – 3 % of bone content by weight, while they add more than 30% of the fracture toughness .
Osteonectin is a 40 kDa acidic and cysteine-rich glycoprotein consisting of a single polypeptide chain that can be broken into 4 domains: 1) a Ca 2+ binding domain near the glutamic acid-rich region at the amino terminus (domain I), 2) a cysteine-rich domain (II), 3) a hydrophilic region (domain III), and 4) an EF hand motif at the carboxy terminus region (domain IV).
The Yellow Card Scheme is a United Kingdom initiative run by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicines (CHM) to gather information on adverse effects to medicines.